Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

634
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
634
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

323
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
323
Neural Regulation01:37

Neural Regulation

39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-scale functional annotation establishes a reference framework for human <i>LRRK2</i> variants.

medRxiv : the preprint server for health sciences·2026
Same author

Single-cell RNA profiling of oligodendroglial lineage cells derived from iPSCs carrying Parkinson's disease-relevant LRRK2-G2019S mutation.

iScience·2026
Same author

Fossil fuel emissions dominate Northern Hemisphere CO<sub>2</sub> seasonal cycle trends under mitigation scenarios.

Nature communications·2026
Same author

National pathways of land-use CO₂ emissions in the 21<sup>st</sup> century.

Nature communications·2026
Same author

Impact of genetic variants in the longevity gene PPARGC1A and cerebrospinal fluid PPARγ levels on clinical trajectories in Parkinson's disease: Potential biomarkers for neurodegeneration and ageing.

Parkinsonism & related disorders·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026

Related Experiment Video

Updated: Aug 6, 2025

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

55.3K

Genetic testing for Parkinson's disease in clinical practice.

Thomas Gasser1

  • 1, Tübingen, Germany. thomas.gasser@med.uni-tuebingen.de.

Journal of Neural Transmission (Vienna, Austria : 1996)
|March 17, 2023
PubMed
Summary

Identifying Parkinson's disease (PD) genetic factors like SNCA, LRRK2, and GBA1 improves understanding of PD pathogenesis. Genetic testing is crucial for patients considering innovative clinical trials.

Keywords:
Disease mechanismsGene mutationsGlucocerebrosidaseLRRK2Parkinson’s diseaseSynuclein

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.6K

Related Experiment Videos

Last Updated: Aug 6, 2025

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

55.3K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.6K

Area of Science:

  • Genetics
  • Neurodegenerative Diseases
  • Molecular Biology

Background:

  • Genetic mutations in SNCA, LRRK2, and GBA1 are key risk factors for Parkinson's disease (PD).
  • Understanding these genetic underpinnings enhances knowledge of PD pathogenesis.
  • Targeted, gene-specific treatments for PD are in development.

Purpose of the Study:

  • To highlight the importance of genetic factors in Parkinson's disease.
  • To emphasize the need for genetic testing awareness among PD patients and families.
  • To encourage genetic testing for patients considering clinical trials.

Main Methods:

  • Review of genetic studies identifying PD-associated genes.
  • Analysis of the role of specific genes (SNCA, LRRK2, GBA1) in PD pathogenesis.
  • Discussion of implications for targeted therapies and clinical trial eligibility.

Main Results:

  • Identification of specific gene mutations (SNCA, LRRK2, GBA1) as significant contributors to PD.
  • Advancement in understanding the molecular mechanisms underlying PD.
  • Development of targeted therapeutic strategies based on genetic findings.

Conclusions:

  • Genetic discoveries have significantly advanced the understanding of Parkinson's disease.
  • Genetic testing is vital for patient stratification in clinical trials and personalized medicine.
  • Increased awareness and accessibility of genetic testing are essential for PD patient care.